Dietary Glutamic Acid Linked to Lower Risk of Colorectal Cancer

This article originally appeared here.
Share this content:
Dietary Glutamic Acid Linked to Lower Risk of Colorectal Cancer
Dietary Glutamic Acid Linked to Lower Risk of Colorectal Cancer

THURSDAY, Jan. 7, 2016 (HealthDay News) -- Dietary glutamic acid intake is associated with reduced risk of developing colorectal cancer (CRC), according to a study published online Dec. 30 in Cancer.

Gilson G. Viana Veloso, M.D., from the Erasmus Medical Center in Rotterdam, Netherlands, and colleagues examined the correlation between dietary glutamic acid intake with CRC risk, and whether the correlation was modified by body mass index (BMI). The study was embedded in the Rotterdam study, which included a prospective cohort of 5,362 adults aged 55 years or older.

The researchers found that 242 subjects developed CRC during follow-up. There was a significant correlation between baseline dietary glutamic acid intake with lower risk of developing CRC (hazard ratio per percent increase in glutamic acid of protein, 0.78; 95 percent confidence interval, 0.62 to 0.99). The risk reduction for CRC by dietary glutamic acid was significant for participants with a BMI of ≤25 kg/m² after stratification by BMI (hazard ratio per percent increase in glutamic acid of protein, 0.58; 95 percent confidence interval, 0.40 to 0.85); no correlation was seen for participants with BMI >25 kg/m² (hazard ratio per percent increase in glutamic acid of protein, 0.97; 95 percent confidence interval, 0.73 to 1.31).

"Our data suggest that baseline dietary glutamic acid intake is associated with a lower risk of developing CRC, but this association may be mainly present in non-overweight subjects," the authors write.

Several authors disclosed financial ties to the nutrition and insurance industries.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths